US EditionA Nitroalkene Derivative Of Salicylate, SANA, Induces Creatine-Dependent Thermogenesis And Promotes Weight Loss - Data Intelligence
Open the article to view the coverage from Plato. Vertical Search. Ai. | PlatoAiStream. Data Intelligence. Vertical Search. Ai.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
An important scientific advance was developed in Uruguay: the compound SANA. A regional drug designed to combat obesity, has successfully completed its initial phase of trials in humans. This achievement positions Uruguay. As a key actor in the search for innovative solutions for metabolic disorders such as obesity and type 2 diabetes. National knowledge Developed by Eolo Pharma, a biotechnological startup arising from collaboration between scie…
The SANA compound completed its initial phase and opens an innovative way to treat obesity and type 2 diabetes.
·Uruguay
Read Full ArticleCoverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
